JP2017525740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525740A5 JP2017525740A5 JP2017512677A JP2017512677A JP2017525740A5 JP 2017525740 A5 JP2017525740 A5 JP 2017525740A5 JP 2017512677 A JP2017512677 A JP 2017512677A JP 2017512677 A JP2017512677 A JP 2017512677A JP 2017525740 A5 JP2017525740 A5 JP 2017525740A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- heterocyclyl
- optionally substituted
- carbocyclyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CN1C(CN*)CCC1 Chemical compound CN1C(CN*)CCC1 0.000 description 5
- DEJNTILJOGNTAQ-UHFFFAOYSA-N CC(C)NCC(C1)N(C)Cc2c1cccc2 Chemical compound CC(C)NCC(C1)N(C)Cc2c1cccc2 DEJNTILJOGNTAQ-UHFFFAOYSA-N 0.000 description 1
- RHFLXMGHOMIKBN-UHFFFAOYSA-N CC(C)NCC(c1ccc(C(F)(F)F)cc1)N(C)C Chemical compound CC(C)NCC(c1ccc(C(F)(F)F)cc1)N(C)C RHFLXMGHOMIKBN-UHFFFAOYSA-N 0.000 description 1
- VMXPDQGFVIAAMN-UHFFFAOYSA-N CC(C)NCC1N(C)CCc2ccccc12 Chemical compound CC(C)NCC1N(C)CCc2ccccc12 VMXPDQGFVIAAMN-UHFFFAOYSA-N 0.000 description 1
- BHWXYAFMHWASNK-UHFFFAOYSA-N CC(C)NCC1N(C)c2ccccc2CC1 Chemical compound CC(C)NCC1N(C)c2ccccc2CC1 BHWXYAFMHWASNK-UHFFFAOYSA-N 0.000 description 1
- BIBOWUAGEFHFBT-UHFFFAOYSA-N CC(C)NCCN(C)CC(F)(F)F Chemical compound CC(C)NCCN(C)CC(F)(F)F BIBOWUAGEFHFBT-UHFFFAOYSA-N 0.000 description 1
- MEEHVVGTARIBOZ-UHFFFAOYSA-N CCCNCC(c1cccc(Cl)c1)N(C)C Chemical compound CCCNCC(c1cccc(Cl)c1)N(C)C MEEHVVGTARIBOZ-UHFFFAOYSA-N 0.000 description 1
- DABATEFTZLWJBQ-UHFFFAOYSA-N CCNCC(C)(c1ccccc1)N(C)C Chemical compound CCNCC(C)(c1ccccc1)N(C)C DABATEFTZLWJBQ-UHFFFAOYSA-N 0.000 description 1
- RBQDUHNRCGKRLO-UHFFFAOYSA-N CN(C)C(CNN=C)c(cc1)ccc1OC Chemical compound CN(C)C(CNN=C)c(cc1)ccc1OC RBQDUHNRCGKRLO-UHFFFAOYSA-N 0.000 description 1
- ALJLAGYCMBXNKO-UHFFFAOYSA-N CN(C)CCN(C)N Chemical compound CN(C)CCN(C)N ALJLAGYCMBXNKO-UHFFFAOYSA-N 0.000 description 1
- BDGGKPZSKHIFAE-NCXKZPMSSA-N CN(C)[C@H](CCCC1)/C1=N/C Chemical compound CN(C)[C@H](CCCC1)/C1=N/C BDGGKPZSKHIFAE-NCXKZPMSSA-N 0.000 description 1
- PYDXFSZUMHNTLD-UHFFFAOYSA-N CNCC(Cc1ccccc1)N(C)C Chemical compound CNCC(Cc1ccccc1)N(C)C PYDXFSZUMHNTLD-UHFFFAOYSA-N 0.000 description 1
- PVFIKWLTVKSXED-UHFFFAOYSA-N CNCCN(C)Cc1ccccc1 Chemical compound CNCCN(C)Cc1ccccc1 PVFIKWLTVKSXED-UHFFFAOYSA-N 0.000 description 1
- DRNLCQNBOWGWJW-DYVFJYSZSA-N C[C@H]([C@@H](c(cc1)ccc1S(c1ccccc1)(=O)=O)N(C)C)NN Chemical compound C[C@H]([C@@H](c(cc1)ccc1S(c1ccccc1)(=O)=O)N(C)C)NN DRNLCQNBOWGWJW-DYVFJYSZSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046770P | 2014-09-05 | 2014-09-05 | |
| US62/046,770 | 2014-09-05 | ||
| PCT/US2015/048174 WO2016036873A1 (en) | 2014-09-05 | 2015-09-02 | Therapeutic compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525740A JP2017525740A (ja) | 2017-09-07 |
| JP2017525740A5 true JP2017525740A5 (enExample) | 2018-10-11 |
| JP6814730B2 JP6814730B2 (ja) | 2021-01-20 |
Family
ID=54140703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512677A Expired - Fee Related JP6814730B2 (ja) | 2014-09-05 | 2015-09-02 | 治療用化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10358437B2 (enExample) |
| EP (1) | EP3189046B1 (enExample) |
| JP (1) | JP6814730B2 (enExample) |
| CN (1) | CN107074823B (enExample) |
| WO (1) | WO2016036873A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6767969B2 (ja) | 2014-09-05 | 2020-10-14 | ジェネンテック， インコーポレイテッド | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
| WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| CN110117271A (zh) * | 2018-02-06 | 2019-08-13 | 中国科学院上海药物研究所 | 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| TWI884745B (zh) * | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2021022163A2 (en) * | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| KR102085758B1 (ko) * | 2019-08-05 | 2020-03-06 | 연세대학교 산학협력단 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
| US12398127B2 (en) | 2019-09-12 | 2025-08-26 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3266556A1 (en) | 2022-09-02 | 2024-03-07 | Auron Therapeutics, Inc. | PYRIDAZINONE DERIVATIVES USED AS KAT2 DEGRADING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
| HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
| BRPI0512902A (pt) | 2004-06-30 | 2008-04-15 | Janssen Pharmaceutica Nv | derivados de ftalazina como inibidores de parp |
| FR2882750B1 (fr) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| FR2933979B1 (fr) * | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| WO2011150183A1 (en) * | 2010-05-28 | 2011-12-01 | Ge Healthcare Limited | Radiolabeled compounds and methods thereof |
| PT2794618T (pt) * | 2011-12-20 | 2017-01-17 | Sanofi Sa | Isotiazolopiridina-2-carboxamidas e seu uso como produtos farmacêuticos |
| UY35103A (es) | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| JP2016519672A (ja) | 2013-03-15 | 2016-07-07 | ジェネンテック， インコーポレイテッド | ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療 |
| JP6767969B2 (ja) | 2014-09-05 | 2020-10-14 | ジェネンテック， インコーポレイテッド | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
| WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
-
2015
- 2015-09-02 WO PCT/US2015/048174 patent/WO2016036873A1/en not_active Ceased
- 2015-09-02 JP JP2017512677A patent/JP6814730B2/ja not_active Expired - Fee Related
- 2015-09-02 EP EP15763755.4A patent/EP3189046B1/en active Active
- 2015-09-02 CN CN201580059718.0A patent/CN107074823B/zh not_active Expired - Fee Related
-
2017
- 2017-03-03 US US15/449,706 patent/US10358437B2/en active Active